Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Background: Limited access to specialist weight management services restricts the implementation of novel pharmacotherapies for obesity such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the UK National Health Service (NHS). Second Nature, a commercial digital health company, offers a remotely delivered program combining a GLP-1RA medication (semaglutide) with digital behavioral support, potentially providing a scalable solution. However, evidence for long-term effectiveness in this real-world context is limited. Objective: This study aimed to evaluate the 12-month effectiveness, feasibility, acceptability, and potential cost-effectiveness of the remotely delivered, semaglutide-supported weight management program by Second Nature. Methods: This retrospective service evaluation analyzed data from participants who initiated the program between September and December 2023. The primary outcome was weight change at 12 months among participants with available data (completers). Secondary outcomes included retention, program engagement (measured by views of the Home screen in the app), behavioral changes, side effects, participant experience (qualitative analysis), and a comparative cost analysis against an NHS specialist weight management service. An “active subscription” was defined as maintaining a paid subscription for the full 12-month period. Descriptive statistics and paired 2-tailed t tests evaluated outcomes. Results: Data from 341 participants were included at baseline (282/341, 82.7% women; mean age 49, SD 11.1 years; mean baseline BMI 37.9, SD 6.9 kg/m2). At 12 months, 39.6% (135/206) maintained an active subscription, while 60.4% (206/341) became inactive. Weight data at 12 months were available for 179 participants (52.5% of the baseline cohort; 100% of active and 19.4% of inactive participants). Among completers who maintained an active subscription, the mean weight loss was 20.0 kg (SD 8.7 kg; P

Original publication

DOI

10.2196/72577

Type

Journal article

Journal

Jmir Formative Research

Publication Date

01/01/2025

Volume

9